Novartis Sues Alvogen To Block Generic Dementia Patch

Law360, New York (January 7, 2013, 7:54 PM EST) -- Novartis AG slapped generic-drug maker Alvogen Group Inc. with a lawsuit in Delaware on Friday, accusing Alvogen of infringing two patents by seeking U.S. regulatory approval to make and sell generic versions of the Exelon patch, a dementia treatment.

Patent co-owners Novartis and LTS Lohmann Therapie-Systeme AG targeted Alvogen and a Pine Brook, N.J.-based Alvogen subsidiary, asking the court to rule that Alvogen had infringed the patent-in-suit and order that the approval of Alvogen's bid for approval of its proposed rivastigmine transdermal products can't come before...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.